利特昔替尼胶囊能生发吗？

Ritexitinib capsules can grow hair. Ritexitinib is effective in treating alopecia areata, including alopecia totalis and alopecia universalis, and a large proportion of patients who use the drug are able to significantly restore hair coverage, improving appearance and quality of life.

About ritexitinib capsules

It is an oral targeted inhibitor of Janus kinase 3 (JAK3). By inhibiting JAK3 and other tyrosine kinase family members, it blocks the activity of signaling molecules and immune cells that lead to the occurrence of diseases such as alopecia areata.

Hair growth effect of ritexitinib capsules

Ritexitinib capsules can significantly increase scalp hair coverage and achieve hair regeneration. After 24 weeks of treatment with the drug, a higher proportion of patients taking ritixitinib 30 mg or 50 mg achieved scalp hair coverage of ≥80%. Therefore, ritexitinib capsules are effective in treating alopecia areata and can help patients improve hair loss symptoms and promote hair regeneration.

What is alopecia areata

Alopecia areata, commonly known as ghost shaving, is an autoimmune disease that causes hair loss due to the immune system attacking the hair follicles of the body. It is a sudden localized patchy hair loss that usually occurs on the scalp, but can also affect facial hair such as eyebrows, eyelashes, and beards, as well as hair in other parts of the body. The purpose of treatment for alopecia areata is to control the progression of the disease, promote hair regeneration, prevent or reduce recurrence, and improve the patient's quality of life.

Study of Ritexitinib Capsules for Hair Growth

In an open-label, long-term Phase 3 study, the safety and effectiveness of Ritexitinib Capsules were evaluated in adult patients with alopecia areata with a hair loss rate of 25% or more, and in 12-year-old adolescent patients with alopecia areata with a hair loss rate of 50% or more.

The results of the study showed that in patients who received 30 mg and 50 mg ritexitinib capsules every day, the proportion of patients with scalp hair covering more than 80% area was significantly higher than that in the placebo group, indicating that ritexitinib capsules can promote hair regeneration and are a suitable treatment option for systemic treatment candidates for alopecia areata.

Among the enrolled patients with a hair loss rate higher than 50%, after 24 weeks of treatment in the once-daily ritexitinib capsule group, 23% of patients had scalp hair coverage of 80% or more, significantly higher than the 1.6% of the placebo group, and 13.4% of patients had scalp hair coverage of more than 90%.

At week 24, ritexitinib capsules showed an improvement of more than 100% in the lesional scalp transcriptome toward the non-lesional direction.

Why ritexitinib capsules can promote hair growth

Ritexitinib capsules are a new type of oral targeted Janus kinase 3 (JAK3) inhibitor, developed by Pfizer. The drug's main mechanism of action is to block the activity of signaling molecules and immune cells by inhibiting the JAK3 and tyrosine kinase families. In alopecia areata, an autoimmune disease, immune cells attack healthy hair follicle cells, causing hair to fall out.

Ritexitinib precisely blocks these signaling pathways, thereby inhibiting excessive activation of the immune system and preventing its attack on hair follicle cells, thus promoting hair regeneration.

Recommended dosage

Ritexitinib capsules are 50 mg, taken once a day, with or without food. Capsules should be swallowed whole and should not be crushed, broken or chewed.

Usage in patients with severe liver damage

It is not recommended for patients with severe liver damage to use ritexitinib capsules for treatment.

Treatment interruption or discontinuation

If treatment with ritexitinib capsules needs to be interrupted, temporary interruption of treatment for less than 6 weeks will not cause significant loss of regrown scalp hair.

Summary

Ritexitinib capsules regulate the immune system and hair follicle growth process through multiple mechanisms, thereby helping to restore hair growth and reduce symptoms of alopecia areata. However, the use of ritexitinib capsules is different, and the degree of hair growth varies from person to person and depends on many factors, such as disease severity, treatment sensitivity, etc.

References:

Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, King B, Banerjee A, Banfield C, Cox LA, Dowty ME, Page K, Vincent MS, Zhang W, Zhu L, Peeva E. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1. PMID: 34863853.

Related hot article recommendations: